Loading…
Curanex Pharmaceuticals Inc is projected to decline to $0.3055 by 2027, a -11% move from its current price of $0.343. CURX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.3292 | $0.3428 | $0.357 | -0.05% |
| May 30 | $0.3236 | $0.3427 | $0.3628 | -0.10% |
| May 31 | $0.3193 | $0.3425 | $0.3674 | -0.15% |
| Jun 1 | $0.3157 | $0.3423 | $0.3712 | -0.20% |
| Jun 2 | $0.3126 | $0.3422 | $0.3746 | -0.25% |
| Jun 3 | $0.3097 | $0.342 | $0.3776 | -0.30% |
| Jun 4 | $0.3071 | $0.3418 | $0.3804 | -0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3071 | $0.3418 | $0.3804 | -0.34% |
| Week 2 | $0.2928 | $0.3406 | $0.3963 | -0.69% |
| Week 3 | $0.282 | $0.3395 | $0.4086 | -1.03% |
| Week 4 | $0.2731 | $0.3383 | $0.4191 | -1.37% |
| Week 5 | $0.2654 | $0.3371 | $0.4283 | -1.71% |
| Week 6 | $0.2585 | $0.336 | $0.4367 | -2.05% |
| Week 7 | $0.2522 | $0.3348 | $0.4444 | -2.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Curanex Pharmaceuticals Inc, ticker CURX, is a healthcare company described as a developmental stage pharmaceutical company that discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc.
and changed its name to Curanex Pharmaceuticals Inc in November 2023.
Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York. The firm operates within the Healthcare sector and focuses on botanical drug development for inflammatory conditions.
These facts together position CURX as a developmental-stage biotech within healthcare, pursuing targeted therapies through Phyto-N across multiple inflammatory-related indications.
CURX is currently priced at $0.3315 per share, reflecting a nascent trading status for a developmental-stage biotechnology name.
The company carries a market capitalization of $9.39M and is ranked 5168 by market cap, highlighting its relatively small scale within the market landscape.
The 30-day range runs from $0.2517 to $0.4366, indicating recent price activity and a trading band around the current level. Technicals show a NEUTRAL sentiment, with RSI(14) at 40 and a 50-day simple moving average of $0.4175. The stock sits above a $0.30 support and below a $0.478 resistance, with annualized volatility around 80%.
A major floor 42.6% below — a decisive break under it would weaken the trend.
The nearest floor, 12.5% below — buyers have tended to step in here.
The nearest ceiling, 38.8% above — a clean break opens room to run.
A major ceiling 60.1% above — clearing it would confirm fresh momentum.
Key CURX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CURX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.333 | Buy | $0.3315 | Buy |
| MA 10 | $0.3196 | Buy | $0.3302 | Buy |
| MA 20 | $0.3392 | Buy | $0.3465 | Sell |
| MA 50 | $0.415 | Sell | $0.3853 | Sell |
| MA 100 | $0.3844 | Sell | $0.5383 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.96 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 9.72 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 6.19 | Buy |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -1.16 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 67.51 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.34 | Buy |
| ADX (14) | 25.14 | Sell |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is NEUTRAL, with the RSI at 40 and the SMA50 noted at $0.4175, suggesting no strong near-term momentum.
Trading activity has been confined within a range from $0.2517 to $0.4366 over the last 30 days, with immediate support at $0.30 and resistance at $0.478. This setup implies a cautious stance for near-term price action.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.268 | $0.343 | $0.4569 | 0% | Neutral | |
| $0.2141 | $0.3055 | $0.4725 | -11% | Neutral | |
| $0.1839 | $0.2811 | $0.4648 | -18% | Bearish | |
| $0.2301 | $0.3736 | $0.6504 | +9% | Neutral | |
| $0.2479 | $0.4253 | $0.7725 | +24% | Bullish | |
| $0.226 | $0.4086 | $0.7699 | +19% | Neutral | |
| $0.2386 | $0.4537 | $0.8831 | +32% | Bullish | |
| $0.2064 | $0.4121 | $0.8258 | +20% | Bullish | |
| $0.1855 | $0.3887 | $0.7998 | +13% | Neutral | |
| $0.2041 | $0.4485 | $0.9456 | +31% | Bullish | |
| $0.2584 | $0.5743 | $1.32 | +67% | Bullish | |
| $0.5559 | $1.24 | $2.84 | +260% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.268 | $0.343 | $0.4084 | +0.00% |
| June 2026 | $0.2753 | $0.3319 | $0.4159 | -3.23% |
| July 2026 | $0.2668 | $0.3279 | $0.4226 | -1.21% |
| August 2026 | $0.2756 | $0.3438 | $0.4527 | +4.86% |
| September 2026 | $0.2728 | $0.3448 | $0.4618 | +0.27% |
| October 2026 | $0.256 | $0.3273 | $0.4453 | -5.06% |
| November 2026 | $0.2513 | $0.3245 | $0.4475 | -0.84% |
| December 2026 | $0.2508 | $0.3272 | $0.4569 | +0.82% |
Click any year to see its month-by-month CURX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CURX is projected to trade between $0.268 and $0.4569, averaging $0.343 — a potential gain of 0% from today's $0.343. A consolidation phase looks the most probable path here.
Curanex Pharmaceuticals Inc's 2027 outlook centres on $0.3055, within a $0.2141 to $0.4725 range. That is -11% versus the projected 2026 average. That marks a -11% change versus current levels. Price action looks broadly range-bound.
By 2028, CURX could reach as high as $0.4648, with a base case around $0.2811 and support toward $0.1839 — roughly -18% from $0.343. Expect choppier, lower action through this leg of the cycle.
Expect CURX to range from $0.2301 to $0.6504 through 2029. The $0.3736 average target implies a +9% move from current prices. That is up +33% on the projected 2028 average. Price action looks broadly range-bound.
The CURX price prediction for 2030 points to an average of $0.4253 (low $0.2479, high $0.7725) — a potential gain of +24% on today's $0.343. Buyers look set to stay in control over this stretch.
In 2031, CURX is projected to trade between $0.226 and $0.7699, averaging $0.4086 — a potential gain of +19% from today's $0.343. That is -4% versus the projected 2030 average. Price action looks broadly range-bound.
Curanex Pharmaceuticals Inc's 2032 outlook centres on $0.4537, within a $0.2386 to $0.8831 range. That is up +11% on the projected 2031 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CURX could reach as high as $0.8258, with a base case around $0.4121 and support toward $0.2064 — roughly +20% from $0.343. Momentum favours further upside here.
Expect CURX to range from $0.1855 to $0.7998 through 2034. The $0.3887 average target implies a +13% move from current prices. That is -6% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The CURX price prediction for 2035 points to an average of $0.4485 (low $0.2041, high $0.9456) — a potential gain of +31% on today's $0.343. Momentum favours further upside here.
In 2040, CURX is projected to trade between $0.2584 and $1.32, averaging $0.5743 — a potential gain of +67% from today's $0.343. That is up +28% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Curanex Pharmaceuticals Inc's 2050 outlook centres on $1.24, within a $0.5559 to $2.84 range. That is up +115% on the projected 2040 average. That marks a +260% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CURX today (≈ 2,915.451895 CURX) could be worth
$3,601.85
+$2,601.85 (+260%) by 2050 · US Dollar
Based on the average projected CURX price of $1.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CURXwould be worth at today's price.
$1,000 invested in CURX on Aug 26, 2025 (≈ 248.75622 CURX) would be worth
$85.32
-$914.68 (-91.5%) today · 0.09× · US Dollar
Based on a CURX entry price of $4.02 vs. today's $0.343.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.333 | $1,030.03 | +3.0% |
| 1 month ago | $0.426 | $805.16 | -19.5% |
| 3 months ago | $0.46 | $745.65 | -25.4% |
| 6 months ago | $0.487 | $704.31 | -29.6% |
| All time ago | $4.02 | $85.32 | -91.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CURX forecast.
Our base-case forecast reaches $0.69 around 2050.
Implied market cap at $0.69: $19.56M
The multi-year forecast shows a path toward higher averages and notable upside in later years. For 2030, the average forecast price is $0.404 with a return on investment of 21.9%, and the sentiment is BULLISH.
The 2040 forecast elevates the average to $0.5482 with a 65.4% ROI and a BULLISH sentiment, signaling meaningful upside if the trajectory unfolds. By 2050, the average forecast reaches $1.16 with a commanding 250.9% ROI and a BULLISH stance, indicating substantial long-term appreciation potential.
Overall, the outlook across these horizons is bullish in the longer term, though shorter windows show mixed sentiment and higher uncertainty. These figures are estimates and not guarantees, and market conditions could alter the path indicated by the forecasts.
Tap a question to reveal the answer.
The average forecast price for 2030 is $0.404 with a 21.9% ROI and a BULLISH sentiment.
The outlook is mixed across years. Bulls appear in 2030, 2040, and 2050 with higher averages (2030 avg $0.404, 2040 avg $0.5482, 2050 avg $1.16), while earlier years show neutral or bearish signals (e.g., 2028 with avg $0.2707 and -18.4% ROI, 2027 with -12.5% ROI). These are forecasts, not guarantees.
Yes. The forecasted maxima include $1.26 in 2040 and $2.68 in 2050, indicating that crossing $1 is within the projected range.
Current price is $0.3315. Market capitalization is $9.39M.
The 30-day range is $0.2517 to $0.4366.
Curanex Pharmaceuticals Inc Community Discussion
0Share your Curanex Pharmaceuticals Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.